Medacta Group Sa ( (MEDGF) ) has released its Q4 earnings. Here is a breakdown of the information Medacta Group Sa presented to its investors.
Medacta Group SA is a Swiss company specializing in the design, production, and distribution of innovative solutions for joint replacement, sports medicine, and spine surgery, with a strong focus on personalized and sustainable medical technologies. In its latest earnings report, Medacta Group SA announced a significant revenue growth of 16.2% in constant currency, reaching EUR 590.6 million, alongside a 19.4% increase in adjusted EBITDA to EUR 160.2 million, reflecting a robust financial performance for 2024. Key highlights include a 54% increase in profit to EUR 72.9 million, an adjusted free cash flow surge to EUR 25.9 million, and a proposed dividend increase to CHF 0.69 per share, demonstrating strong operational and financial management. The company achieved notable growth across all geographic regions and product lines, particularly in the knee and extremities segments, supported by innovative product launches and strategic market expansions. Looking ahead, Medacta targets revenue growth of 13% to 15% in constant currency for 2025, with an adjusted EBITDA margin around 27%, as it continues to expand its product offerings and market presence.